<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="9" ids="16796">Melatonin</z:chebi> exerts strong anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> activity via several mechanisms, including anti-proliferative and pro-apoptotic effects in addition to its potent <z:chebi fb="11" ids="22586">antioxidant</z:chebi> activity </plain></SENT>
<SENT sid="1" pm="."><plain>Several studies have investigated the effects of <z:chebi fb="9" ids="16796">melatonin</z:chebi> on <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">haematological malignancies</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>However, the previous studies investigating lymphoid <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> have been largely restricted to a single type of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e>, Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) </plain></SENT>
<SENT sid="3" pm="."><plain>Thus, we examined the actions of <z:chebi fb="9" ids="16796">melatonin</z:chebi> on the growth and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in a small panel of cell lines representing different human lymphoid <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> including Ramos (Epstein-Barr virus-negative <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>), SU-DHL-4 (diffuse large B cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>), DoHH2 (follicular B non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo>) and JURKAT (<z:hpo ids='HP_0011009'>acute</z:hpo> T cell <z:mpath ids='MPATH_336'>leukaemia</z:mpath>) </plain></SENT>
<SENT sid="4" pm="."><plain>We showed that <z:chebi fb="9" ids="16796">melatonin</z:chebi> promotes cell cycle arrest and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in <z:hpo ids='HP_0000001'>all</z:hpo> these cells, although there was marked variations in responses among different cell lines (sensitivity; Ramos/DoHH2 &gt; SU-DHL-4 &gt; JURKAT) </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="9" ids="16796">Melatonin</z:chebi>-induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> was relatively rapid, with increased caspase 3 and PARP cleavage detected within 0.5-1 h following <z:chebi fb="9" ids="16796">melatonin</z:chebi> addition </plain></SENT>
<SENT sid="6" pm="."><plain>Moreover, there was evidence for rapid processing of both caspase 9, as well as a breakdown of the <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> inner transmembrane potential </plain></SENT>
<SENT sid="7" pm="."><plain>On the contrary, caspase activation was detected only in SU-DHL-4 and Ramos cells following <z:chebi fb="9" ids="16796">melatonin</z:chebi> treatment suggesting that the extrinsic pathway does not make a consistent contribution to <z:chebi fb="9" ids="16796">melatonin</z:chebi>-induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in malignant lymphocytes </plain></SENT>
<SENT sid="8" pm="."><plain>Although <z:hpo ids='HP_0000001'>all</z:hpo> cell lines expressed the high-affinity <z:chebi fb="9" ids="16796">melatonin</z:chebi> receptors, MT1 and MT2, <z:chebi fb="9" ids="16796">melatonin</z:chebi>-induced caspase activation appeared to be independent these receptors </plain></SENT>
<SENT sid="9" pm="."><plain>Our findings confirm that <z:chebi fb="9" ids="16796">melatonin</z:chebi> could be a potential chemotherapeutic/preventive agent for malignant lymphocytes </plain></SENT>
<SENT sid="10" pm="."><plain>However, it is necessary to take into account that different lymphoid <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> may differ in their response to <z:chebi fb="9" ids="16796">melatonin</z:chebi> </plain></SENT>
</text></document>